What is THREAD?
THREAD operates at the intersection of clinical research technology and specialized consulting, providing a comprehensive decentralized research platform. By integrating electronic clinical outcome assessments (eCOA) with scalable study design tools, the company enables biopharma firms and contract research organizations (CROs) to conduct more efficient, patient-centric trials. Recognized as a leader in the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology, THREAD has established itself as a foundational partner for organizations seeking to transition from traditional, site-based models to flexible, remote-capable research frameworks. Its platform is engineered to enhance participant engagement while maintaining rigorous scientific standards across diverse geographic locations.
The company's market position is bolstered by its ability to bridge the gap between complex regulatory requirements and the need for rapid, data-driven clinical development. By streamlining the operational complexities of modern trials, THREAD facilitates a more inclusive research environment, effectively reducing the barriers to entry for both study participants and clinical sites.
How much funding has THREAD raised?
THREAD has raised a total of $50M across 1 funding round:
Private Equity
$50M
Private Equity (2020): $50M with participation from Water Street and JLL Partners
Key Investors in THREAD
Water Street
A Chicago-based private equity firm that specializes exclusively in the health care sector, providing strategic capital to growth-stage companies.
JLL Partners
A middle-market private equity firm with a long-standing history of investing in health care services and medical technology companies.
What's next for THREAD?
With the infusion of this major enterprise-level funding, THREAD is poised to deepen its investment in product innovation and global market expansion. The strategic roadmap likely involves enhancing the interoperability of its eCOA solutions and expanding its consulting footprint to support the increasing demand for hybrid and fully decentralized trial models. As the biopharma industry continues to prioritize digital transformation, THREAD's focus on scalable, patient-centric infrastructure will be instrumental in maintaining its competitive advantage. The company is expected to leverage this capital to further solidify its leadership in the PEAK Matrix assessment, driving the next generation of clinical research efficiency and data integrity.
See full THREAD company page
